{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:43:10Z","timestamp":1788864190739,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In this multicenter, open-label, single-arm, Phase II study with Simon two-stage optimum design (NCT04361370), we investigate the efficacy and safety of triplet maintenance (olaparib, pembrolizumab, bevacizumab) in patients with platinum-sensitive recurrent ovarian cancer who are wild-type for\n                    <jats:italic>BRCA<\/jats:italic>\n                    1\/2. A total of 44 patients were enrolled, and the median follow-up duration was 22.9 months (interquartile range: 17.4\u201324.7). The primary outcome was 6-months progression-free survival (PFS), which was 88.6% (95% confidence interval [CI] 75.4\u201396.2), meeting the pre-specified primary endpoint. The secondary outcomes reported here include median PFS, 12-months PFS, and overall survival and safety. The median PFS was 22.4 months (20.4\u2013\u221e), with a 12-months PFS rate of 84.0% (95% CI 69.3\u201392.0). The median overall survival was 28.6 months (27.3\u2013\u221e). The combination demonstrated tolerable toxicity with manageable side effects. Other secondary outcomes include time-to-progression, time to subsequent treatment, time to second treatment and PFS2; however, this data is not reported, as treatment is still ongoing in a majority of patients. Exploratory analysis shows that patients who were homologous recombination deficiency-positive or had a programmed death-ligand 1 combined positive score \u22651 showed a favorable response (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.043 and\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001, respectively). Thus, triplet maintenance shows durable efficacy with tolerable safety in patients with platinum-sensitive recurrence.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-40829-2","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T13:01:32Z","timestamp":1694005292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4"],"prefix":"10.1038","volume":"14","author":[{"given":"Yoo-Na","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-8795","authenticated-orcid":false,"given":"Boram","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Gie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8342-8701","authenticated-orcid":false,"given":"Sang Wun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chel Hun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"YL Ngoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"SP Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-1350","authenticated-orcid":false,"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"40829_CR1","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata, S., Cecere, S. C., Du Bois, A., Harter, P. & Heitz, F. Treatment of recurrent ovarian cancer. Ann. Oncol. 28, viii51\u2013viii56 (2017).","journal-title":"Ann. Oncol."},{"key":"40829_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander, M. et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21, 771\u2013775 (2011).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"40829_CR3","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","volume":"35","author":"S Pignata","year":"2017","unstructured":"Pignata, S. et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study. J. Clin. Oncol. 35, 3347\u20133353 (2017).","journal-title":"J. Clin. Oncol."},{"key":"40829_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","volume":"119","author":"M Friedlander","year":"2018","unstructured":"Friedlander, M. et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br. J. Cancer 119, 1075\u20131085 (2018).","journal-title":"Br. J. Cancer"},{"key":"40829_CR5","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"40829_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"40829_CR7","unstructured":"Food and Drug Administration (FDA). Lynparza Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s013lbl.pdf (2020)."},{"key":"40829_CR8","unstructured":"European Medicines Agency (EMA). Lynparza Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lynparza-epar-medicine-overview_en.pdf (2020)."},{"key":"40829_CR9","unstructured":"Parker, A. China Approves Lynparza in Ovarian Cancer. https:\/\/www.biocentury.com\/article\/297563\/china-approves-lynparza-in-ovarian-cancer (2018)."},{"key":"40829_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2014.10.020","volume":"136","author":"DE Cohn","year":"2015","unstructured":"Cohn, D. E. et al. A cost-utility analysis of NRG Oncology\/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. Gynecol. Oncol. 136, 293\u2013299 (2015).","journal-title":"Gynecol. Oncol."},{"key":"40829_CR11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2021.12.025","volume":"164","author":"A Poveda","year":"2022","unstructured":"Poveda, A. et al. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1\/BRCA2 mutation: OPINION primary analysis. Gynecol. Oncol. 164, 498\u2013504 (2022).","journal-title":"Gynecol. Oncol."},{"key":"40829_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 779\u2013791 (2017).","journal-title":"Lancet Oncol."},{"key":"40829_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039\u20132045 (2012).","journal-title":"J. Clin. Oncol."},{"key":"40829_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu, J. F. et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 15, 1207\u20131214 (2014).","journal-title":"Lancet Oncol."},{"key":"40829_CR15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"40829_CR16","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.3802\/jgo.2022.33.e45","volume":"33","author":"JY Lee","year":"2022","unstructured":"Lee, J. Y. et al. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. J. Gynecol. Oncol. 33, e45 (2022).","journal-title":"J. Gynecol. Oncol."},{"key":"40829_CR17","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert, E. J. et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin. Cancer Res. 26, 4268\u20134279 (2020).","journal-title":"Clin. Cancer Res."},{"key":"40829_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"40829_CR19","doi-asserted-by":"crossref","unstructured":"Banerjee, S. I. et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO Congress 2022 (ESMO, 2022).","DOI":"10.1016\/j.annonc.2022.07.657"},{"key":"40829_CR20","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382\u20131392 (2012).","journal-title":"N. Engl. J. Med."},{"key":"40829_CR21","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620\u2013631 (2021).","journal-title":"Lancet Oncol."},{"key":"40829_CR22","doi-asserted-by":"publisher","first-page":"TPS5598","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5598","volume":"37","author":"P Harter","year":"2019","unstructured":"Harter, P. et al. DUO-O: a randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. J. Clin. Oncol. 37, TPS5598\u2013TPS5598 (2019).","journal-title":"J. Clin. Oncol."},{"key":"40829_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"40829_CR24","unstructured":"Kurtz, J. E. P.-L. et al. A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab. GINECO-OV236b\/ENGOT-ov29. ESMO Congress 2022 (ESMO, 2022)."},{"key":"40829_CR25","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.3802\/jgo.2021.32.e31","volume":"32","author":"YJ Lee","year":"2021","unstructured":"Lee, Y. J. et al. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J. Gynecol. Oncol. 32, e31 (2021).","journal-title":"J. Gynecol. Oncol."},{"key":"40829_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"40829_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64\u201370 (2015).","journal-title":"Ann. Oncol."},{"key":"40829_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer 4, 16 (2018).","journal-title":"NPJ Breast Cancer"},{"key":"40829_CR29","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776\u20131782 (2012).","journal-title":"Br. J. Cancer"},{"key":"40829_CR30","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","volume":"72","author":"T Popova","year":"2012","unstructured":"Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation. Cancer Res. 72, 5454\u20135462 (2012).","journal-title":"Cancer Res."},{"key":"40829_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak, N. J. et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2, 366\u2013375 (2012).","journal-title":"Cancer Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40829-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40829-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40829-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T14:34:10Z","timestamp":1700145250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40829-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40829"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-40829-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MSD supported the study by providing the study drugs (olaparib and pembrolizumab). J.Y.L., B.G.K., and J.W.K. received grants from the MSD during the conduct of the study. J.Y.L. received grants and personal fees from AstraZeneca, Beigene, Bergenbio, Clovis Oncology, Immunogen, Janssen, Merck, Novartis, Roche, Seagen, Synthon, and Takeda. B.G.K. received grants from AstraZeneca, Cellid, and Utilex. J.W.K. received personal fees from AstraZeneca, Janssen, Takeda, GSK, Boryung, CMIC, LG Pharma, and Vifor Pharma. D.S.T.\u00a0reports personal fees for advisory board membership from AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Genmab, GSK, MSD, and Roche; personal fees as an invited speaker from AstraZeneca, Eisai, GSK, Merck Serono, MSD, Roche, and Takeda; ownership of stocks\/shares of Asian Microbiome Library (AMiLi); institutional research grants from AstraZeneca, Bayer, Karyopharm Therapeutics, and Roche; institutional funding as coordinating PI from AstraZeneca and Bergen Bio; institutional funding as local PI from Bayer, Byondis B.V. and Zeria Pharmaceutical Co Ltd; a previous non-renumerated role as Chair of the Asia- Pacific Gynecologic Oncology Trials Group (APGOT); a previous non-renumerated role as the Society President of the Gynecologic Cancer Group Singapore; non-renumerated membership of the Board of Directors of the GCIG; and product samples from AstraZeneca, Eisai, and MSD (non-financial interest).\u00a0N.Y.N. received personal fees from AstraZeneca and Pfizer. Otherwise, the authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5476"}}